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Abstract
Essential tremor (ET) is a common cause of significant disability, but its etiologies and 
pathogenesis are poorly understood. Research has been hampered by the variable definition of ET 
and by non-standardized research approaches. The National Institute of Neurological Disorders 
and Stroke (USA) invited experts in ET and related fields to discuss current knowledge, 
controversies, and gaps in our understanding of ET and to develop recommendations for future 
research. Discussion focused on phenomenology and phenotypes, therapies and clinical trials, 
pathophysiology, pathology, and genetics. Across all areas, the need for collaborative and 
coordinated research on a multinational level was expressed. Standardized data collection using 
common data elements for genetic, clinical, neurophysiological, and pathological studies was 
recommended. Large cohorts of patients should be studied prospectively to collect bio-samples, 
characterize the natural history of the clinical syndrome including patient-oriented outcomes, 
investigate potential etiologies of various phenotypes, and identify pathophysiological 
mechanisms. In particular, cellular and system-level mechanisms of tremor oscillations should be 
elucidated because they may yield effective therapeutic targets and biomarkers. A neuropathology 
consortium was recommended to standardize postmortem analysis and further characterize 
neuropathological observations in the cerebellum and elsewhere. Furthermore, genome-wide 
association studies on large patient cohorts (~10,000 patients) may allow the identification of 
common genes contributing to risk, and whole exome or genome sequencing may enable the 
identification of genetic risk and causal mutations in cohorts and well-characterized families.
Keywords
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INTRODUCTION
Essential tremor (ET) affects approximately 1% of the general population and 5% of the 
population over 65 years of age [1]. Despite this high prevalence, there is no satisfactory 
pharmacologic treatment, the pathological findings are debated, the underlying genes have 
been elusive, the mechanisms of neural network oscillation are unknown, and the clinical 
definition of ET has been inconsistent. There are several tangible reasons that may account 
for the lack of a breakthrough in ET research. ET remains poorly defined and can be 
diagnosed only on clinical grounds. The main challenges are the lack of stringent diagnostic 
criteria and the lack of biomarkers. Efforts in ET genetics have been impeded by 
"phenocopies" that share the phenotype but not the genetic cause, and by genetically 
heterogeneous changes that present as a syndrome similar to ET. The importance of an 
accurate diagnosis to study the underlying disease mechanism also applies to the 
investigation of the pathophysiology and pathology in ET.
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In May 2015, the National Institute of Neurological Disorders and Stroke, National 
Institutes of Health, USA held a workshop to discuss current knowledge gaps in ET and to 
identify research opportunities regarding ET phenomenology and phenotypes, clinical trials, 
mechanisms of tremorogenic oscillation, pathology, and genetics. The goal was to develop 
consensus recommendations for future research, which are presented herein along with a 
summary discussion for the following topic areas: phenomenology and phenotypes, 
therapies and clinical trials, physiology, pathology, genetics (table 1).
Phenomenology and phenotypes
The 1998 MDS consensus criteria define “classic ET” as a monosymptomatic disorder with 
bilateral, largely symmetric postural or kinetic tremor involving the hands and forearms that 
is visible and persistent, or as isolated head tremor in the absence of dystonic posturing [2]. 
However, many have challenged this narrow definition and have expanded the phenotype of 
ET to include subtle cerebellar abnormalities [3], cognitive dysfunction [4], hearing 
abnormalities [5, 6], and dystonia [7]. Furthermore, it is common for investigators to deviate 
from the MDS criteria, and patients fulfilling the MDS criteria subsequently may develop 
signs of Parkinson disease (PD), dystonia and other disorders [8]. As published prevalence 
estimates of ET vary and genetic risks likely are multiple [9], it is probable that the term ET 
encompasses multiple disorders [10]. Although the MDS criteria exclude abnormal 
neurological signs other than tremor, delineating the core phenotypic features of ET is 
challenging and somewhat arbitrary because there is no diagnostic marker for ET. 
Furthermore, the common occurrence of subtle or questionable dystonia, parkinsonism, or 
ataxia creates additional diagnostic uncertainty, regardless of how ET is defined. Moreover, 
the clinical significance of incident tremor in the upper limbs depends on age of onset; the 
development of monosymptomatic upper extremity tremor after age 65 is associated with 
higher risk of incident PD, incident dementia, and mortality [11–14].
While tremor is a common feature of dystonia, the relationship of tremor in one area (e.g., 
head, voice, upper limb) to dystonia elsewhere is uncertain and frequently debated. It is 
unclear to what extent task-specific and focal tremors are forms of ET, dystonia, or separate 
disorders. Dystonic disorders with known genetic causes, such as DYT24, may present with 
isolated postural and action tremor suggesting that the phenotypic heterogeneity of dystonia 
may include presentations with isolated tremor[15].
There was general agreement that ET is a common clinical syndrome, not a specific disease, 
and that this syndrome should be defined and used consistently among clinicians and 
researchers. Other isolated tremors and isolated tremor syndromes (e.g., isolated head 
tremor, isolated task-specific writing tremor, and isolated voice tremor) should not be 
referred to as ET or variants of ET. Over time, some patients may convert to an alternate 
phenotype, resulting in a change in diagnosis years after the initial syndromic diagnosis of 
ET. By defining ET as a clinical syndrome, no inference can be made regarding etiologies. 
To establish a link between clinical presentation and potential etiologies, phenotypic data 
should be documented to the fullest extent possible, including signs of uncertain 
significance.
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Recommendations
• Regard ET as a specific, common isolated tremor syndrome, not a specific 
disease. Other monosymptomatic tremors should be referred to as isolated tremor 
syndromes, not essential tremors.
• Define ET as an isolated tremor syndrome of unknown etiology in which there is 
bi-brachial action tremor (i.e., postural and/or kinetic tremor) with a duration of 
at least three years, with or without head tremor or tremor in other regions. A 
duration of three years is usually sufficient time to rule out alternate diagnoses. 
There should be no other diagnostic neurologic signs, such as overt dystonia or 
parkinsonism, or evidence of endogenous (e.g., autoimmune disease) or 
exogenous (e.g., toxins) disturbances that could cause tremor. Difficulty with 
tandem walking is permissible, but there should be no abnormality of gait.
• Apply the definition of ET consistently in clinical and research settings.
• Prospectively study large multi-national cohorts of individuals with ET and other 
isolated tremor syndromes (e.g., isolated head tremor, isolated voice tremor, and 
other focal and task-specific tremors), using validated assessment tools and 
standardized terminology (i.e., common data elements) [16] . Such studies will 
improve our understanding of the phenotype and natural history of ET and its 
relationship to other isolated tremor syndromes.
• Collect biospecimens using standardized protocols to aid in elucidating 
underlying etiologies, pathophysiology, therapeutic targets, and biomarkers. 
Broad subject consent is important to all allow for data and sample sharing.
• Capture neurologic signs and symptoms to the fullest extent possible to ensure 
unbiased and careful phenotyping. Tremulous people in ET pedigrees and 
population studies will frequently have neurologic signs and symptoms of 
uncertain significance.
Therapies and clinical trials
Studying the tremor-modulating properties of pharmacological agents in ET allows 
inferences on potential tremor mechanisms and may facilitate the development of novel 
therapeutic agents. Ethanol significantly reduces tremor amplitude in many patients with ET, 
but data on the sensitivity and specificity of a symptomatic benefit are sparse[16–20]. 
Ethanol’s CNS actions are mediated through many receptor types, including GABA-A, 
NMDA, glycine, and G-protein-activated inwardly rectifying potassium channels. Other 
potential mechanisms of ethanol’s impact on ET include decreased rhythmic neuronal firing 
via modulation of T-type calcium channels and blockade of gap junctions [21]. The clinical 
effect of ethanol has stimulated research into related molecules such as sodium oxybate, 1-
octanol and the 1-octanol metabolite octanoic acid as potential therapies in ET [22–24].
Many antiepileptic drugs have been explored in ET, including agents acting on the 
GABAergic system (e.g., benzodiazepines, barbiturates) and various ion channels that 
mediate neuronal membrane stability and oscillation. Of the drugs having some efficacy in 
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ET, primidone and topiramate inhibit sodium channels, and topiramate and gabapentin 
inhibit calcium channels and glutamatergic transmission.
The beneficial effect of beta-blockers on ET is often quite pronounced but poorly 
understood. Potential mechanisms include peripheral beta-2 adrenergic antagonism on 
skeletal muscle and muscle spindles and central blockade of adrenergic and serotoninergic 
receptors [25, 26].
Reduced tremor amplitude is the principal measure of clinical efficacy in ET and is often 
viewed as a surrogate for functional improvement. Several clinical rating scales with 
validated clinimetric properties are available, including the Essential Tremor Rating 
Assessment Scale (TETRAS) [27] Fahn-Tolosa-Marin scale (FTM) [28], Bain and Findley 
Tremor Rating and Spirography [29], and the Washington Heights-Inwood Genetic Study of 
Essential Tremor scale (WHIGET) [30]. These scales, the Quality of Life in Essential 
Tremor Questionnaire [31], and the Bain and Findley Tremor ADL Scale were 
recommended by the MDS Task Force on Tremor for use in clinical practice and trials[32].
Interest has grown in the use of portable motion transducers (e.g., accelerometers, 
gyroscopes, digitizing tablets) to objectively measure tremor amplitude. Unfortunately, the 
advantages of high linear precision and sensitivity of transducers are mitigated by the large 
random variability in tremor amplitude. Consequently, the minimum detectable change in 
tremor amplitude exceeding random variability is comparable for transducers and the 
clinical rating scales mentioned above [32, 33]. Nevertheless, transducers are capable of 
capturing tremor severity continuously throughout the day and do not require a clinician to 
be present at the time of recording. Yet, clinically meaningful changes have not been 
determined for existing scales or transducers.
There are several surgical treatments for ET, including thalamic deep brain stimulation, or 
thalamotomy via surgical or magnetic resonance guided focused lesioning. The investigation 
of the neurophysiological properties of tremorogenic oscillations may lead to the 
identification of novel targets and treatment strategies.
Recommendations
• Utilize outcome measures (e.g., rating scales, motion transducers, patient 
reported outcomes) that capture functionally relevant changes in clinical trials in 
ET.
• Determine clinically meaningful changes for individuals with ET and other 
isolated tremor syndromes. The relationship between patient reported outcomes, 
clinical assessment scales, and motion transducers should be evaluated.
• Characterize the influence of tremor subtype and comorbid conditions (e.g., 
depression, anxiety, cognitive impairment) on treatment response.
• Collect data via standardized approaches in order to allow comparisons between 
studies. Such efforts may be facilitated by the development of common data 
elements.
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• Develop and validate novel technologies (e.g., long-term tremor monitors) for 
use in natural history cohorts and clinical trials. The validity, reliability, 
minimum detectable change, and clinically meaningful change should be 
determined for these devices and compared with those for rating scales.
• Develop novel, cost-effective, efficient trial designs to rapidly evaluate new 
therapies for efficacy or futility.
Physiology
It has long been known that ET arises from an abnormal CNS oscillator since ET frequency 
is not affected by limb inertia or reflex loop time [34]. There is growing evidence that the 
corticobulbocerebellothalamocortical circuit is the main source of central tremorogenic 
oscillation [35–38]. However, oscillations involving this circuit occur in many forms of 
tremor, and the principal abnormalities specific to ET are still unknown [39–41].
Thalamic neurons in the cerebellar relay nucleus ventralis intermedius (VIM) exhibit 
rhythmic bursts of activity that are correlated with tremor in electromyography (EMG) [37]. 
A lesion or deep brain stimulation (DBS) targeting VIM reduces the tremor amplitude, as 
does injection of the GABA-A agonist muscimol [42]. Results from studies using 
magnetoencephalography, electroencephalography, positron emission tomography and 
functional magnetic resonance imaging suggest that the motor cortex also plays an important 
role in ET [43–45].
Positron emission tomography has revealed increased GABA-A receptor binding of 11C-
flumazenil in the ventrolateral thalamus, the dentate nucleus of the cerebellum, and the 
premotor cortex in ET [46]. Alpha-1 GABA-A receptor subunit knock-out mice exhibit 
tremor with many characteristics of ET [47, 48]. The tremorogenic olivocerebellar 
oscillation produced by harmaline in laboratory animals has long been viewed as animal 
model of ET [49, 50], but conclusive evidence of olivary dysfunction in patients with ET is 
lacking.
Recommendations
• Determine the mechanisms of oscillation in the 
corticobulbocerebellothalamocortical circuit and the roles played by each node 
of this oscillating circuit. In particular, the cellular mechanisms of oscillations in 
this circuit, their relative contribution to postural and kinetic components of 
tremor, and the effect of lesions and DBS should be thoroughly characterized.
• Use imaging and neurophysiological techniques to identify CNS patterns of 
activation and interactions that are specific to ET.
• Develop suitable animal models for further study of tremorogenic oscillation.
Pathology
The goals of defining the neuropathologic changes associated with ET are (1) to 
complement and support physiology studies, (2) to understand the cellular processes 
associated with cellular injury and progression in order to develop treatments, (3) to identify 
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pathologic endophenotypes that may allow for recognition of distinct genetic or clinical 
variants, and (4) to define relationships with other forms of neurodegeneration.
The relationship between neuropathologic findings and clinical symptomatology can be 
complex and has yet to be elucidated in ET. Such complexity is observed in other disorders 
such as Alzheimer disease (AD), where there is progressive accumulation of plaques and 
tangles with synapse and neuron loss along with inflammatory responses, yet the threshold 
of lesions that results in a given individual developing dementia varies and the lesion 
distribution and potential downstream effects can greatly shape clinical presentation. While 
many neurologic disorders have neuropathologically identifiable substrates, assuming that 
the appropriate brain region is examined with the relevant method, there remain others, such 
as many cases of epilepsy, where the tools of neuropathology are too crude and too static to 
detect the functional alterations which lead to dysfunction.
Neuropathologic information about many neurologic diseases comes only from autopsy 
cases and is therefore cross-sectional data with effectively arbitrary endpoints. The ability to 
study the neuropathology of diseases only at the endpoint complicates interpretation of 
initiating events, progression, and heterogeneity. When insights into progression have been 
gained directly from such studies, large numbers of cases representing a wide range of 
clinical states have been required(as done by Braak for both neurofibrillary tangles and 
Lewy bodies [51]). Additionally, because ET does not spread throughout the body, it is not 
possible to define anatomic regions as “at risk” or as “pre-symptomatic” at the time of 
autopsy, as can be done with other disorders such as ALS where all motor neurons will 
eventually be involved if lifespan allows.
When considering the neuropathologic underpinnings of ET, it will be necessary to (1) 
examine the appropriate brain regions with consideration of somatotopic mapping in order to 
understand symptoms, (2) apply a wide range of histologic methods with functional markers 
to detect relevant changes, (3) recognize the potential impact of intercurrent or contributing 
disease processes such as Lewy bodies and cerebrovascular disease, and (4) sample a wide 
range of subjects with varying degrees of deficits to gain insight into disease progression at 
the structural level.
Currently, autopsy studies of ET are limited to relatively small numbers of elderly patients 
with advanced disease. With only a few groups examining the brains from subjects with ET, 
there have been conflicting reports of findings that are complicated by varied approaches to 
examination (including differences in sampling protocols, staining and assessment methods, 
and subject/control definitions).
The neuropathologic studies in ET have focused primarily on cerebellum and brainstem 
(including the inferior olives and locus coeruleus) with disagreement over whether there is 
neurodegeneration in ET [52, 53]. One group has focused on quantitative studies using a 
standardized section of parasagittal neocerebellum (anterior and posterior quadrangulate 
lobules in the anterior lobe of the cerebellar cortex: lobules IV–VI), which is involved in 
motor control [54, 55]. This group has observed structural changes in Purkinje cells and 
neighboring neurons as well as a reduction in Purkinje cell linear density with “empty 
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baskets” and Purkinje cell heterotopias. In contrast, two other groups have not detected a 
reduction in Purkinje cells in ET [56–59]. In addition to the changes in Purkinje cell number, 
one group has defined a number of changes in the dendritic, axonal and synaptic architecture 
of the cerebellum [53, 54, 60–67], which have not been examined by other investigators. The 
differing results regarding Purkinje cell loss in ET may stem from differences in study 
design, including definitions of cases/controls, sampling of the cerebellum, sample size, 
and/or the methods of quantification and more detailed study [56, 67, 68]. Similar issues 
may explainthe conflicting observations regarding Lewy bodies in ET, with some groups 
reporting higher frequency [52] and other reporting no difference from controls [57].
A critical deficit in the reported autopsy studies is a mapping of lesion burden onto 
neuroanatomic somatotopy. Does pathology lie in the brain regions that are associated with 
the body segment affected by ET while being absent or less frequent in comparable 
anatomic sites for which a body segment is not affected? The observation that comes 14 
closest to addressing this critical issue of whether morphologic changes align with disease 
phenotype comes from the study of a small number of cases with asymmetric tremor in 
which there was reasonable correlation between the side of tremor and the greater burden of 
structural changes [69]
Recommendations
• Develop standardized methods for gross and microscopic examination.
• Utilize standardized, unbiased selection criteria and clinical documentation for 
the collection, sharing, and analysis of postmortem tissues from patients and 
controls.
• Prospectively collect phenotypic and pathology data to allow for 
clinicopathologic correlations.
Genetics
It is highly unlikely that there is a single causal genetic abnormality in ET[9]. Work on gene 
discovery in ET probably has been hampered by a high phenocopy rate, non-Mendelian 
inheritance, locus heterogeneity in monogenic ET, and a lack of diagnostic biomarkers. 
Estimates of the proportion of ET patients with a positive family history vary between 20% 
and 90% [70–72]. Twin studies in the United States and in Denmark/Germany found 
pairwise concordance rates between 0.60 and 0.93 for monozygotic twins versus 0.27 and 
0.29 for dizygotic twins, indicating a high heritability between 45% and 90% [73, 74]. 
Nevertheless, ET genetics still awaits a breakthrough discovery that improves the 
understanding of this disorder.
Early linkage analyses of ET families using polymorphic DNA markers revealed linkage to 
three chromosomal regions: chromosome 13q13 (ETM1) [75], chromosome 2p24 (ETM2) 
[76], and chromosome 6p23 (ETM3) [77]. However, the causative genes and mutations have 
not been found. More recently, whole exome sequencing has been used in multiple ET 
families to identify rare or novel variants, and several potential candidate genes have been 
reported: FUS (fused in sarcoma; OMIM *137070), HTRA2 (serine peptidase; OMIM 
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*606441), TENM4 (teneurin transmembrane protein 4, OMIM *610084), SORT1 (sortilin, 
15 OMIM *602458), and SCN4A (voltage-gated sodium channel, type 4, alpha subunit, 
OMIM *603967)[78–81]. These findings have not been confirmed in other cohorts [82–85].
Genome-wide genotyping of single nucleotide polymorphisms (SNPs) has been used to test 
for the association of common DNA variants with ET susceptibility. The Icelandic DeCode 
consortium performed the first ET genome-wide association study (GWAS), finding an 
association between ET and SNPs in the region of LINGO1. The most significant SNP, 
rs9652490, met genome-wide significance in the combined analysis of both stages of the 
study [86]. Although replication studies have not consistently found an association with 
LINGO1, most studies of LINGO1 and protein functions and interactions have continued to 
support this gene as promising candidate [87–89]. A German GWAS showed association 
between SNPs in the SLC1A2 gene region and ET, but the best SNP did not attain genome-
wide significance in the replication stage [90]. Recently, a large GWAS of ET cases from 
Europe and North America detected association with SNPs in 3 chromosomal regions near 
STK32B, PPARGC1A and CTNNA3 [91]. Further replication in independent data sets is 
essential.
Recommendations
• Develop and use common data elements for phenotyping ET.
• Collect a large sample of approximately 10,000 ET cases to allow for well-
powered genotype-phenotype association studies. The ideal would be prospective 
collection, yet existing samples could be considered if appropriate phenotyping 
is ensured. The involvement of lay ET associations and advocacy groups would 
greatly contribute to the accomplishment of this goal. Outreach should be global.
• Store DNA and other bio-samples in a centrally located bank or in multiple 
locally-maintained biobanks, consented for broad sharing among researchers.
• Phenotype, collect, bank, and genotype pedigree-based (family) and sporadic ET 
cases through multi-national collaborations.
• Elucidate the full allelic spectrum and the estimated heritability by analyzing 
large ET samples (using e.g., GWAS, and new sequencing techniques such as 
exome or genome sequencing)
DISCUSSION
Several important themes emerged from the discussions and recommendations of this 
workshop. First, ET should be recognized as a common clinical syndrome, not a specific 
disease. ET should be defined and the term used consistently. The definition of ET should 
not impede or deter researchers from defining and studying other isolated tremor syndromes, 
but these syndromes should be clearly distinguished from ET. This novel syndromic 
definition recognizes that ET is a common phenotypic presentation of multiple different 
etiologies.
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A second recurring theme was the need for common data elements to standardize the 
characterization and study of ET and other isolated tremor syndromes. Common data 
elements can be expected to facilitate international collaborations and data sharing. 
Furthermore, outcome measures utilized in clinical trials should capture functionally 
relevant changes across the phenotypic spectrum of ET.
Third, ET is a very common clinical syndrome, but it appears to be genetically 
heterogeneous. Therefore, large numbers of patients are needed for genetic research. Studies 
characterizing the phenotype-genotype relations in ET will require standardized data 
collection, multinational collaboration, and strong support from lay ET associations and 
advocacy groups.
Finally, the success of functional neurosurgery illustrates that a single treatment can be very 
effective for tremors of diverse etiology and pathophysiology. The etiologic heterogeneity 
and syndromic definition of ET are not incompatible with the design of valid clinical trials 
and the discovery of effective pharmacotherapy. Further elucidation of tremorogenesis in the 
corticobulbocerebellothalamocortical loop should provide important new directions toward 
more effective treatment.
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Highlights
• More collaborative and coordinated research across all disciplines is needed 
for future research in ET.
• Standardized data collection using common data elements are required.
• Very large cohorts of patients should be studied prospectively on a 
multinational level.
• Characterization of the natural history of the ET syndromes is needed.
• A neuropathology consortium should be formed and bio-samples should be 
collected.
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